Publicaciones en colaboración con investigadores/as de Hospital de Mataró (20)

2024

  1. Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis

    Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537

2023

  1. Impact of days elapsed from the onset of symptoms to hospitalization in COVID-19 in-hospital mortality: Time matters

    Revista Clinica Espanola, Vol. 223, Núm. 5, pp. 281-297

  2. Nosocomial COVID-19: A Nationwide Spanish Study

    Gerontology, Vol. 69, Núm. 6, pp. 671-683

2022

  1. Clinical Features and Risk Factors for Mortality Among Long-term Care Facility Residents Hospitalized Due to COVID-19 in Spain

    Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 77, Núm. 4, pp. E138-E147

  2. Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry

    Internal and Emergency Medicine, Vol. 17, Núm. 4, pp. 1115-1127

  3. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 761-775

  4. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

2021

  1. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

  2. Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 Registry

    PLoS ONE, Vol. 16, Núm. 2 February

  3. Prognostic Significance of Concomitant Superficial Vein Thrombosis in Patients with Deep Vein Thrombosis of the Lower Limbs

    Thrombosis and Haemostasis, Vol. 121, Núm. 12, pp. 1650-1659

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

2019

  1. An international perspective on hospitalized patients with viral community-acquired pneumonia

    European Journal of Internal Medicine, Vol. 60, pp. 54-70

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Nationwide study on the use of intravascular catheters in internal medicine departments

    Journal of Hospital Infection, Vol. 90, Núm. 2, pp. 135-141

  3. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study

    HIV Medicine, Vol. 16, Núm. 10, pp. 628-634

  4. Virological failure to raltegravir in Spain: Incidence, prevalence and clinical consequences

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 11, pp. 3087-3095

2014

  1. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2012

  1. Long-term benefits of nevirapine-containing regimens: Multicenter study with 506 patients, followed-up a median of 9 years

    Current HIV Research, Vol. 10, Núm. 6, pp. 513-520

2008

  1. Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release

    Cardiovascular Therapeutics, Vol. 26, Núm. 2, pp. 91-100